Skip to main navigation
Loading
  • News
  • Investors
  • Careers
  • Contact
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home
  • Menu Menu

Press Releases

  • Overview
  • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Stock Lookup
    • Analyst Coverage
  • Press Releases
  • Corporate Governance
    • Leadership
    • Board of Directors
    • Committee Composition
    • IRS – Required Disclosures
  • SEC Filings
    • Quarterly Results
  • Contact
  • Email Alerts
  • CORRECTION – KemPharm Announces Corporate Name Change to Zevra Therapeutics

    02-22-2023

  • KemPharm Enhances Senior Management Team

    01-31-2023

  • KemPharm Issues Letter to Shareholders

    01-24-2023

  • KemPharm Partners with the Hypersomnia Foundation to Support Sleep Disorder Research and Advocacy

    01-18-2023

  • KemPharm Announces Promotion of Sven Guenther, Ph.D., to Chief Scientific Officer and Christal Mickle, M.A., to Chief Product Development Officer

    01-11-2023

  • KemPharm Announces Board and Leadership Changes to Support its Transformation into a Leading Rare Disease Company

    01-09-2023

  • KemPharm Announces Initiation of Phase 2 Clinical Trial Investigating KP1077 for the Treatment of Idiopathic Hypersomnia (IH)

    12-21-2022

  • KemPharm Announces Appointment of Christopher Posner as New Independent Director

    11-29-2022

  • KemPharm Receives FDA Orphan Drug Designation for Serdexmethylphenidate (SDX) for the Treatment of Idiopathic Hypersomnia (IH)

    11-18-2022

  • KemPharm Reports Third Quarter 2022 Results

    11-09-2022

Pagination
  • First page «
  • Previous page ‹
  • Page 1
  • Current page 2
  • Page 3
  • Page 4
  • …
  • Next page ›
  • Last page »
  • About Us
    • Our Mission & Vision
    • The Zevra Story
    • Leadership
    • Board of Directors
  • Our Approach
    • What We Do
    • Partnering
  • Patients & Providers
    • Niemann-Pick Disease Type C
    • Sleep Disorders
    • Expanded Access Policy
  • Science & Pipeline
    • Pipeline
    • Clinical Trials
    • Products
    • Publications & Presentations
  • Investors
    • Investor Relations
    • Events & Presentations
    • Stock Information
    • Press Releases
    • Corporate Governance
    • SEC Filings
    • Contact
    • Email Alerts
  • Careers
    • Culture
    • Job Openings
  • Contact
    • info@zevra.com
    • 888.958.1253
    • Facebook
    • Twitter
    • LinkedIn
  • Home

© 2023 Zevra Therapeutics, Inc. All rights reserved. Privacy Policy | Terms of Use

Scroll to top